-
Patent Agency Ranking
公开(公告)号：US20170082644A1
公开(公告)日：2017-03-23
申请号：US15363376
申请日：2016-11-29
Applicant: Zora Biosciences OY
Inventor： Reijo Laaksonen , Kim Ekroos , Reini Hurme , Riikka Katainen , Minna Janis , Kirill Tarasov
IPC: G01N33/92
CPC classification number: G01N33/92 , G01N2570/00 , G01N2800/10 , G01N2800/2871 , G01N2800/325
Abstract: The present invention inter alia provides a method, and uses thereof, of predicting statin-induced muscle toxicity or its complications, such as myalgia, myopathy and rhabdomyolysis, by detecting the lipid concentrations or lipid-lipid concentration ratios of a biological sample and comparing them to a control. This method has identified lipid markers that are more specific and sensitive in detecting these statin-induced muscle toxicity than the currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, statin-induced muscle toxicity. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of statin-induced muscle toxicity.
-
2.发明申请LIPIDOMIC BIOMARKERS FOR THE PREDICTION OF CARDIOVASCULAR OUTCOMES IN CORONARY ARTERY DISEASE PATIENTS NOT UNDERGOING STATIN TREATMENT 有权用于预防冠状动脉疾病患者心脏病变的不良生物标志物不能接受治疗公开(公告)号：US20140295467A1
公开(公告)日：2014-10-02
申请号：US14356594
申请日：2012-11-07
Applicant: ZORA BIOSCIENCES OY
Inventor： Reijo Laaksonen , Kim Ekroos , Reini Hurme , Minna Jänis , Riikka Katainen , Kirill Tarasov
IPC: G01N33/92
CPC classification number: G01N33/92 , G01N2570/00 , G01N2800/042 , G01N2800/32 , G01N2800/324 , G01N2800/50 , G01N2800/70
Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.
Abstract translation: 本发明尤其提供了通过检测生物样品的脂质浓度或脂质比例并将其与对照进行比较来预测严重的CVD并发症如AMI或CVD死亡的方法及其用途，并且鉴定了特异性脂质标记物 在预测这些CVD并发症方面比目前使用的临床标志物更具体和灵敏。 还提供了针对所述脂质的抗体及其用于预测，诊断，预防和/或治疗CVD并发症的用途。 本发明另外涉及包含脂质和/或其抗体的试剂盒，用于CVD并发症的预测和/或诊断。
-
3.发明授权Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment 有权用于预测未接受他汀类药物治疗的冠状动脉疾病患者的心血管结局的脂质体生物标志物公开(公告)号：US09052328B2
公开(公告)日：2015-06-09
申请号：US14356594
申请日：2012-11-07
Applicant: Zora Biosciences OY
Inventor： Reijo Laaksonen , Kim Ekroos , Reini Hurme , Minna Jänis , Riikka Katainen , Kirill Tarasov
IPC: G01N33/92
CPC classification number: G01N33/92 , G01N2570/00 , G01N2800/042 , G01N2800/32 , G01N2800/324 , G01N2800/50 , G01N2800/70
Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.
Abstract translation: 本发明尤其提供了通过检测生物样品的脂质浓度或脂质比例并将其与对照进行比较来预测严重的CVD并发症如AMI或CVD死亡的方法及其用途，并且鉴定了特异性脂质标记物 在预测这些CVD并发症方面比目前使用的临床标志物更具体和灵敏。 还提供了针对所述脂质的抗体及其用于预测，诊断，预防和/或治疗CVD并发症的用途。 本发明另外涉及包含脂质和/或其抗体的试剂盒，用于CVD并发症的预测和/或诊断。
-
4.发明授权Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment 有权用于预测冠状动脉疾病患者接受他汀类药物治疗的心血管结局的脂质体生物标志物公开(公告)号：US09052327B2
公开(公告)日：2015-06-09
申请号：US14356474
申请日：2012-11-07
Applicant: Zora Biosciences OY
Inventor： Reijo Laaksonen , Kim Ekroos , Reini Hurme , Minna Jänis , Riikka Katainen , Kirill Tarasov
IPC: G01N33/92
CPC classification number: G01N33/92 , G01N2405/00 , G01N2560/00 , G01N2570/00 , G01N2800/32 , G01N2800/324 , G01N2800/325 , G01N2800/50 , G01N2800/70 , H01J49/0027
Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.
Abstract translation: 本发明尤其提供了通过检测生物样品的脂质浓度或脂质比例并将其与对照进行比较来预测严重的CVD并发症如AMI或CVD死亡的方法及其用途，并且鉴定了特异性脂质标记物 在预测这些CVD并发症方面比目前使用的临床标志物更具体和灵敏。 还提供了针对所述脂质的抗体及其用于预测，诊断，预防和/或治疗CVD并发症的用途。 本发明另外涉及包含脂质和/或其抗体的试剂盒，用于CVD并发症的预测和/或诊断。
-
5.发明申请LIPIDOMIC BIOMARKERS FOR THE PREDICTION OF CARDIOVASCULAR OUTCOMES IN CORONARY ARTERY DISEASE PATIENTS UNDERGOING STATIN TREATMENT 有权用于预防静脉血栓治疗的冠状动脉疾病患者心脏血管成像的生物标记物公开(公告)号：US20140295466A1
公开(公告)日：2014-10-02
申请号：US14356474
申请日：2012-11-07
Applicant: Zora Biosciences OY
Inventor： Reijo Laaksonen , Kim Ekroos , Reini Hurme , Minna Jänis , Riikka Katainen , Kirill Tarasov
IPC: G01N33/92
CPC classification number: G01N33/92 , G01N2405/00 , G01N2560/00 , G01N2570/00 , G01N2800/32 , G01N2800/324 , G01N2800/325 , G01N2800/50 , G01N2800/70 , H01J49/0027
Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.
Abstract translation: 本发明尤其提供了通过检测生物样品的脂质浓度或脂质比例并将其与对照进行比较来预测严重的CVD并发症如AMI或CVD死亡的方法及其用途，并且鉴定了特异性脂质标记物 在预测这些CVD并发症方面比目前使用的临床标志物更具体和灵敏。 还提供了针对所述脂质的抗体及其用于预测，诊断，预防和/或治疗CVD并发症的用途。 本发明另外涉及包含脂质和/或其抗体的试剂盒，用于CVD并发症的预测和/或诊断。
-
-
-
-
Search Results
5
records
(took 0.031 seconds)
